ARA-290 (also known as Cibinetide) is an exciting research peptide that's gaining attention for its potential to support nerve repair, reduce inflammation, and promote tissue healingβwithout stimulating red blood cell production like erythropoietin (EPO). Instead, ARA-290 activates the body's Innate Repair Receptor (IRR), which is involved in repairing damaged tissues and calming inflammation. β¨ Potential Research Benefits Current research suggests ARA-290 may help support: π§ Nerve regeneration π₯ Reduced neuroinflammation β‘ Relief from neuropathic (nerve) pain π¦Ά Improved symptoms of small fiber and diabetic neuropathy π©Ή Tissue healing and repair β€οΈ Reduced inflammatory signaling throughout the body π Potential improvements in metabolic health markers (observed in some studies) One of the biggest advantages is that, unlike EPO, ARA-290 has not been shown to increase red blood cell counts or hematocrit, making it unique among peptides derived from erythropoietin. π Research Dosing There is currently no FDA-approved dosing protocol, but published human studies have commonly used: β
4 mg daily - Subcutaneous injection - 28 consecutive days Other research has evaluated: β’ 1 mg daily β’ 4 mg daily β’ 8 mg daily Interestingly, studies found 4 mg daily produced similar benefits to 8 mg daily, suggesting higher doses may not provide additional advantages. Some research communities also explore protocols such as: β’ 2 mg twice weekly β’ 2β4 mg every other day These are community protocols and are not established clinical recommendations. π§ͺ Reconstitution with PBS ARA-290 is commonly reconstituted with sterile Phosphate Buffered Saline (PBS) because it tends to dissolve more readily than with bacteriostatic water. Example: 10 mg vial β Add 1 mL PBS Final concentration: 10 mg/mL βοΈ 1 mg = 10 units βοΈ 2 mg = 20 units βοΈ 4 mg = 40 units βοΈ Storage β’ Refrigerate after reconstitution (36β46Β°F / 2β8Β°C) β’ Protect from light β’ Gently swirl to dissolveβavoid vigorous shaking